Kamfanin Insiliko Medicine da aka jera a kasuwar hada-hadar kudi ta Hong Kong ya sanar da kulla yarjejeniyar hadin gwiwa tare da kamfanin Eli Lilly daga Amurka, wanda ke nufin haɓaka sabbin magunguna ta hanyar amfani da fasahar artificial intelligence. Yarjejeniyar, wacce aka bayyana a ranar Litinin, ta kunshi biyan farko na 115 million dollars, kuma kimar ta na iya kaiwa 2.75 billion dollars, bisa ga cimma manufofin ci gaba da na kasuwanci.
Insiliko Medicine, wacce ke da hedikwata a Amurka, na kokarin fadada amfani da sabbin fasahohinta a fannin magunguna, inda wannan yarjejeniyar ke ba ta damar amfana daga kwarewar Eli Lilly a fannin haɓaka magunguna, wanda zai karfafa damar samun nasara a binciken da za a yi nan gaba.
Bayani kan Yarjejeniyar
Yarjejeniyar ta kunshi bayar da sabis na dandamalin fasahar artificial intelligence na Insiliko Medicine a fannonin bincike da ci gaba, wanda ke ba Eli Lilly damar samun sabbin fasahohi don inganta tasirin magunguna. Hakanan, yarjejeniyar ta kunshi yiwuwar samun karin kudaden shiga da suka danganci cimma manufofi a matakai daban-daban na ci gaba.
Wannan yarjejeniyar na daya daga cikin manyan yarjejeniyoyi a fannin haɓaka magunguna ta hanyar amfani da artificial intelligence, wanda ke nuna karuwar sha'awa wajen amfani da sabbin fasahohi a masana'antar magunguna. Ana sa ran wannan hadin gwiwa zai taimaka wajen hanzarta ci gaban sabbin magunguna, wanda zai amfanar da marasa lafiya a duk duniya.
Asali da Yanayi
Insiliko Medicine an kafa ta a shekarar 2014, kuma tana daga cikin kamfanonin da suka fi kwarewa wajen amfani da artificial intelligence a fannin haɓaka magunguna. Kamfanin ya samu nasarori masu yawa a cikin 'yan shekarun nan, inda ya haɓaka sabbin magunguna da dama ta hanyar amfani da sabbin fasahohinsa. A gefe guda, Eli Lilly na daga cikin manyan kamfanonin magunguna a duniya, tana da tarihin dogon lokaci a fannin haɓaka magunguna don magance nau'ikan cututtuka da dama.
Wannan yarjejeniyar na zuwa ne a lokacin da fannin magunguna ke fuskantar canje-canje masu yawa wajen amfani da sabbin fasahohi, inda kamfanoni ke kokarin inganta ingancin bincike da ci gaba da rage farashi. Hakanan, annobar COVID-19 ta hanzarta wannan yanayi, inda kamfanoni suka gane muhimmancin gaggawa wajen kirkirar sabbin hanyoyi don magance kalubalen lafiyar duniya.
Tasiri da Sakamakon
Wannan yarjejeniyar na zama mataki na dabaru ga kowanne daga cikin kamfanonin, inda zai ba Insiliko Medicine damar karfafa gwanintarta a kasuwa, yayin da Eli Lilly za ta amfana daga sabbin kirkire-kirkiren fasaha da Insiliko ke bayarwa. Ana sa ran wannan hadin gwiwa zai inganta sakamakon bincike da kuma bayar da sabbin magunguna cikin gaggawa.
Bugu da kari, wannan yarjejeniyar na iya shafar kasuwa gaba daya, inda hakan zai iya karfafa wasu kamfanoni su zuba jari a fannonin fasahar artificial intelligence, wanda zai iya haifar da sabbin kirkire-kirkire a fannin haɓaka magunguna. Hakanan, wannan yarjejeniyar na nuna karuwar sha'awa wajen hadin gwiwa tsakanin kamfanoni a fannin bincike da ci gaba.
Tasirin a Yankin Arab
A lokacin da kasashen Arab ke kokarin karfafa gwanintarsu a fannin bincike da fasaha, wannan yarjejeniyar na iya zama misali mai kyau. Kasashen Arab na iya amfana daga hadin gwiwa tare da kamfanoni na duniya a fannonin kamar haɓaka magunguna da artificial intelligence, wanda zai taimaka wajen inganta kula da lafiya a yankin.
Hakanan, zuba jari a fannonin fasahar artificial intelligence na iya bude sabbin hanyoyi na kirkire-kirkire a kasashen Arab, wanda zai taimaka wajen cimma ci gaban da ya dore da kuma karfafa tattalin arzikin ilimi.